ArticleJCO precision oncology2020
Pathogenic Germline DNA Repair Gene and
Article in JCO precision oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Incorporating Structured and Unstructured Data Sources to Identify and Characterize Hereditary Cancer Testing Among Veterans With Metastatic Castration-Resistant Prostate Cancer.JCO clinical cancer informatics · 2025Article
- Hereditary and Familial Traits in Urological Cancers and Their Underlying Genes.European urology open science · 2024Article
- Article
- Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.European urology open science · 2023Article
- Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study.BMC cancer · 2022Article
- Germline Variants in DNA Damage Repair Genes andJCO precision oncology · 2022Article
- Germline pathogenic variants in unselected Korean men with prostate cancer.Investigative and clinical urology · 2022Article
- DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men.JNCI cancer spectrum · 2022Article
- Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion.JCO precision oncology · 2021Article
- Germline HOXB13 G84E Variant in a Patient with Gastric and Prostate Cancer: A Case Report and Literature Review.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
purposeGermline mutations in DNA repair (DR) genes and susceptibility genes PATIENTS AND
methodsTo evaluate the frequency of pathogenic/likely pathogenic germline variants (PVs/LPVs) in men with mPC, this study sequenced 38 DR genes,
resultsAll pathogenic variants were found in men self-reported as white, with a carrier frequency of 8.5% (DR genes, 7.3%;
conclusionThese findings demonstrate a lower prevalence of germline PVs/LPVs in an unselected, predominantly white mPC cohort than previously reported, which may have implications for the design of clinical trials testing targeted therapies. Larger studies in broad and diverse populations are needed to more accurately define the prevalence of germline mutations in men with mPC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.